A Phase 3 interventional study of gemcitabine and docetaxel in Breast Cancer, Breast Neoplasms and Cancer of the Breast, sponsored by Eli Lilly and Company. Completed at 65 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2002, is one of 15 in phase 3, and was the 22nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 9 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 475 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 13th largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2002, is one of 16 in phase 3, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. The experimental arm will receive gemcitabine 1000 mg/m2 intravenous (IV) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 IV day 1 over 1 hour repeated every three weeks. The comparator arm will receive docetaxel 75 mgm/m2 IV day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. Patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. Patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gemcitabine · Drug: docetaxel
Drug: docetaxel · Drug: capecitabine
1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
Also known as: LY188011, Gemzar
75 mg/m2, intravenous (IV), every 21 days until disease progression
1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
Time to Disease Progression (Initial Treatment)
Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.
Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months)
Time to Disease Progression (Crossover Treatment)
For crossover treatment, time to disease progression (TTDP) was defined as the number of months between the first dose date of crossover treatment and the date of disease progression or the date of death due to disease under study, whichever came first. TTDP for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. TTDP censored at earliest of: 1)date of death not due to disease; or 2)date of last contact for participants alive without disease progression; or 3)start date of other anti-tumor therapy due to progression.
Time frame: Date of first dose of crossover treatment to date of first-documented disease progression after receiving first crossover treatment or date of death due to study disease, whichever came first (up to 82 months)
Progression-Free Survival (Initial Treatment)
For initial treatment, progression-free survival (PFS) was defined as the number of months between the date of randomization and the date of first documented disease progression or the date of death due to any cause, whichever came first. Time to PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for progression; or 3) first dose date of crossover treatment.
Time frame: Date of randomization until the date of first documented progression or date of death from any cause, whichever came first (up to 82 months)
Progression-Free Survival (Crossover Treatment)
For crossover treatment, progression-free survival (PFS) was defined as the number of months between first dose date of crossover treatment and date of documented disease progression or date of death due to any cause, whichever came first. PFS for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for participants with documented disease progression.
Time frame: First dose date of crossover treatment to date of first-documented progression after receiving crossover treatment or date of death due to any cause, whichever came first (up to 82 months)
Duration of Response (Initial Treatment)
Among tumor responders, duration of tumor response was measured from the date of response (complete response \[CR\] or partial response \[PR\] until the first date of documented progression or death from any cause. Duration of response was censored at the earliest of: 1) date of last contact for participants alive without disease progression (DP); or 2) start date of other anti-tumor therapy for DP; or 3) dose date of crossover treatment.
Time frame: Date of response (CR or PR) until the first date of documented progression or death from any cause (up to 82 months)
Duration of Response (Crossover Treatment)
At crossover treatment, duration of response was measured from the time criteria were met for complete response (CR) or partial response (PR), until first date that recurrent or progressive disease was objectively documented or date of death due to any cause, whichever came first. This definition only applied to those who crossed over \& achieved CR or PR in crossover treatment. Duration of response censored at earliest of: 1) date of last contact for those alive without disease progression; or 2) start date of other anti-tumor therapy for documented disease progression.
Time frame: Date of CR or PR until first date of recurrent or progressive disease after receiving crossover treatment was objectively documented or date of date due to any cause, whichever came first (up to 82 months)
Overall Survival
Overall survival time was defined as the number of months between the date of randomization and the date of death due to any cause. The overall survival time was censored at the date of last contact for participants who were still alive.
Time frame: Date of randomization to date of death from any cause (up to 82 months)
Best Overall Response (Initial Treatment)
Best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.
Time frame: Best response from start of treatment until disease progression/recurrence (up to 82 months)
Best Overall Response (Crossover Treatment)
Best overall response was the best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response assessed using RECIST criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.
Time frame: Best response from start of treatment until disease progression/recurrence (up to 82 months)
Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Initial Treatment)
KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).
Time frame: Baseline until crossover treatment began (up to 82 months)
Summary of Changes in Karnofsky Performance Status (KPS) by Treatment (Crossover Treatment)
KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).
Time frame: First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 moths)
Summary of Changes in Rotterdam Symptom Checklist (RSCL) by Treatment (Initial Treatment)
RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].
Time frame: Baseline until crossover treatment began (up to 82 months)
Summary of Changes in Rotterdam Symptom Checklist by Treatment (Crossover Treatment)
RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].
Time frame: First day of crossover treatment until end of crossover treatment at trial discontinuation (up to 82 months)
| Milestone | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Started | 239 | 236 |
| Received initial treatment | 236 | 227 |
| Completed | 98 | 83 |
| Not completed | 141 | 153 |
| Withdrew: Adverse event | 43 | 67 |
| Withdrew: Physician decision | 40 | 31 |
| Withdrew: Withdrawal by subject | 40 | 28 |
| Withdrew: Lost to follow-up | 0 | 6 |
| Withdrew: Other | 18 | 21 |
| Milestone | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Started | 77 | 81 |
| Received treatment | 76 | 80 |
| Completed | 50 | 53 |
| Not completed | 27 | 28 |
| Withdrew: Adverse event | 8 | 8 |
| Withdrew: Physician decision | 7 | 7 |
| Withdrew: Withdrawal by subject | 6 | 9 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Other | 4 | 3 |
For crossover treatment, time to disease progression (TTDP) was defined as the number of months between the first dose date of crossover treatment and the date of disease progression or the date of death due to disease under study, whichever came first. TTDP for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. TTDP censored at earliest of: 1)date of death not due to disease; or 2)date of last contact for participants alive without disease progression; or 3)start date of other anti-tumor therapy due to progression.
| months | Capecitabine | Gemcitabine |
|---|---|---|
| Time to Disease Progression (Crossover Treatment) | 4.51 (2.11 to 7.80) | 2.34 (2.04 to 3.78) |
For initial treatment, progression-free survival (PFS) was defined as the number of months between the date of randomization and the date of first documented disease progression or the date of death due to any cause, whichever came first. Time to PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for progression; or 3) first dose date of crossover treatment.
| months | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Progression-Free Survival (Initial Treatment) | 9.01 (7.73 to 10.53) | 8.88 (7.27 to 10.89) |
For crossover treatment, progression-free survival (PFS) was defined as the number of months between first dose date of crossover treatment and date of documented disease progression or date of death due to any cause, whichever came first. PFS for crossover treatment only applied to those participants who crossed over from initial treatment to crossover treatment. PFS was censored at the earliest of: 1) date of last contact for participants alive without disease progression; or 2) start date of other anti-tumor therapy for participants with documented disease progression.
| months | Capecitabine | Gemcitabine |
|---|---|---|
| Progression-Free Survival (Crossover Treatment) | 4.51 (2.11 to 7.80) | 2.34 (2.04 to 3.78) |
Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.
| months | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Time to Disease Progression (Initial Treatment) | 9.28 (7.73 to 10.79) | 8.88 (7.37 to 11.05) |
Among tumor responders, duration of tumor response was measured from the date of response (complete response \[CR\] or partial response \[PR\] until the first date of documented progression or death from any cause. Duration of response was censored at the earliest of: 1) date of last contact for participants alive without disease progression (DP); or 2) start date of other anti-tumor therapy for DP; or 3) dose date of crossover treatment.
| months | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Duration of Response (Initial Treatment) | 9.11 (7.60 to 11.94) | 10.39 (8.22 to 13.75) |
At crossover treatment, duration of response was measured from the time criteria were met for complete response (CR) or partial response (PR), until first date that recurrent or progressive disease was objectively documented or date of death due to any cause, whichever came first. This definition only applied to those who crossed over \& achieved CR or PR in crossover treatment. Duration of response censored at earliest of: 1) date of last contact for those alive without disease progression; or 2) start date of other anti-tumor therapy for documented disease progression.
| months | Capecitabine | Gemcitabine |
|---|---|---|
| Duration of Response (Crossover Treatment) | 25.89 (4.64 to 45.03) | 42.50 (16.02 to 48.22) |
Overall survival time was defined as the number of months between the date of randomization and the date of death due to any cause. The overall survival time was censored at the date of last contact for participants who were still alive.
| months | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Overall Survival | 22.99 (18.82 to 25.69) | 23.29 (18.55 to 25.53) |
Best overall response was the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.
| participants | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Complete Response (confirmed) | 6 | 6 |
| Partial Response (confirmed) | 71 | 79 |
| Stable Disease | 96 | 90 |
| Progressive Disease | 32 | 27 |
| Unknown | 34 | 34 |
Best overall response was the best response recorded from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response assessed using RECIST criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that did not meet above criteria.
| participants | Capecitabine | Gemcitabine |
|---|---|---|
| Complete Response (confirmed) | 1 | 1 |
| Partial Response (confirmed) | 10 | 6 |
| Stable Disease | 19 | 20 |
| Progressive Disease | 34 | 36 |
| Unknown | 13 | 18 |
KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).
| units on a scale | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Baseline | 90.85 ± 8.159 | 90.09 ± 8.335 |
| Change from Baseline | -3.30 ± 9.259 | -3.27 ± 9.118 |
KPS ranges from 0 to 100, subdivided into three categories: incapacitated (0-40), self-care (50-70), and normal activity (80-100).
| units on a scale | Capecitabine | Gemcitabine |
|---|---|---|
| Baseline | 89.09 ± 7.174 | 87.94 ± 9.360 |
| Change from Baseline | -0.30 ± 7.839 | -1.27 ± 9.068 |
RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].
| units on a scale | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| Baseline | 68.09 ± 25.103 | 72.32 ± 23.693 |
| Change from Baseline | 2.42 ± 27.093 | -2.68 ± 26.685 |
RSCL includes 4 scales to assess quality of life (QOL) endpoints: 1) a 23-item physical distress level with scale score ranges from 23 to 92 \[low score represents better QOL\] 2)a 7-item psychological distress level with scale score ranges from 7 to 28\[low score represents better QOL\] 3)8-item activity level with scale score ranges from 8 to 32 \[high score represents better QOL\]; 1-item overall valuation of life with score range from 1 to 7 \[low score represents better QOL\].
| units on a scale | Capecitabine | Gemcitabine |
|---|---|---|
| Baseline | 75.00 ± 20.876 | 76.39 ± 17.663 |
| Change from Baseline | -2.78 ± 21.029 | -0.69 ± 27.133 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine Plus Docetaxel | — | 72/237 (30.4%) | 233/237 (98.3%) |
| Docetaxel Plus Capecitabine | — | 55/226 (24.3%) | 221/226 (97.8%) |
| Event | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 25/237 | 7/226 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/237 | 9/226 |
| LeukopeniaBlood and lymphatic system disorders | 6/237 | 2/226 |
| PyrexiaGeneral disorders | 4/237 | 5/226 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/237 | 0/226 |
| DiarrhoeaGastrointestinal disorders | 2/237 | 4/226 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/237 | 4/226 |
| Pericardial effusionCardiac disorders | 4/237 | 0/226 |
| VomitingGastrointestinal disorders | 4/237 | 3/226 |
| DehydrationMetabolism and nutrition disorders | 4/237 | 2/226 |
| Event | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 193/237 | 73/226 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 15/237 | 129/226 |
| FatigueGeneral disorders | 129/237 | 120/226 |
| NauseaGastrointestinal disorders | 113/237 | 118/226 |
| DiarrhoeaGastrointestinal disorders | 111/237 | 108/226 |
| AnaemiaBlood and lymphatic system disorders | 113/237 | 59/226 |
| AlopeciaSkin and subcutaneous tissue disorders | 86/237 | 98/226 |
| Peripheral sensory neuropathyNervous system disorders | 78/237 | 83/226 |
| LeukopeniaBlood and lymphatic system disorders | 86/237 | 25/226 |
| VomitingGastrointestinal disorders | 71/237 | 74/226 |
| Age Continuous(years) | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine | Total |
|---|---|---|---|
| Mean | 55.8 ± 11.77 | 54.6 ± 11.60 | 55.2 ± 11.69 |
| Sex: Female, Male(Participants) | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine | Total |
|---|---|---|---|
| Female | 237 | 1 | 238 |
| Male | 2 | 235 | 237 |
| Region of Enrollment(participants) | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine | Total |
|---|---|---|---|
| United States | 173 | 166 | 339 |
| Taiwan | 15 | 18 | 33 |
| Mexico | 14 | 15 | 29 |
| Puerto Rico | 4 | 1 | 5 |
| Argentina | 11 | 13 | 24 |
| Brazil | 1 | 1 | 2 |
| Australia | 11 | 12 | 23 |
| Korea, Republic of | 10 | 10 | 20 |
| Karnofsky Performance Status-Baseline(units on a scale) | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine | Total |
|---|---|---|---|
| <=60 Needs increasing assistance up to Death (0) | 0 | 0 | 0 |
| 70 - Unable to carry on normal activity | 16 | 15 | 31 |
| 80 - Activity with effort; some signs of disease | 44 | 40 | 84 |
| 90 - Normal activity; minor signs of disease | 101 | 101 | 202 |
| 100 - Normal no complaints; no evidence of disease | 74 | 75 | 149 |
| Missing | 4 | 5 | 9 |
| Race/Ethnicity(participants) | Gemcitabine Plus Docetaxel | Docetaxel Plus Capecitabine | Total |
|---|---|---|---|
| Caucasian | 160 | 158 | 318 |
| African Descent | 23 | 12 | 35 |
| Oriental | 28 | 30 | 58 |
| Hispanic | 26 | 36 | 62 |
| Other | 2 | 0 | 2 |
The record gives a start of Feb 2002, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine